INVEST study warns on too-low BP in diabetic patients with CAD.
The INVEST (INternational VErapamil SR-Trandolapril) study, a very large international study of hypertensive patients, has shown that patients with type 2 diabetes and coronary artery disease do not benefit from tightening systolic blood pressure levels to below 130 mmHg, and this may in some cases be harmful.
Aalbers
J
J
D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001794:Blood Pressure / Q000502:physiology*; D003226:Congresses as Topic; D003324:Coronary Artery Disease / Q000150:complications* / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D000959:Antihypertensive Agents